4 terminated, 1 completed. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 4, Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow LY2140023: new trials by email Literature Review of LY2140023 trials Research Report on LY2140023
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Safety Study of Pomaglumetad Methionil in Schizophrenia Pomaglumetad methionil - Schizophrenia | Phase 3 | Terminated | Denovo Biopharma LLC | 129 | 2011-12-01 | 2026-09-14 |
| A Physical Dependence Study in Schizophrenia LY2140023, Placebo - Schizophrenia | Phase 3 | Completed | Denovo Biopharma LLC | 123 | 2011-11-01 | 2022-09-14 |
| A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients LY2140023, Aripiprazole - Schizophrenia | Phase 3 | Terminated | Denovo Biopharma LLC | 678 | 2011-04-01 | 2022-09-07 |
| A Study of LY2140023 in Patients With Schizophrenia LY2140023, Placebo - Schizophrenia | Phase 3 | Terminated | Denovo Biopharma LLC | 567 | 2011-03-01 | 2022-10-18 |
| A Long-Term, Open-Label, Study on Schizophrenia LY2140023, Olanzapine, Aripiprazole - Schizophrenia | Phase 2 / Phase 3 | Terminated | Denovo Biopharma LLC | 560 | 2010-06-01 | 2026-09-14 |
Schizophrenia (5)
United States (5) · Puerto Rico (4) · Austria (2) · France (2) · Germany (2) · Greece (2) · Mexico (2) · Poland (2) · Romania (2) · Russia (2) · Spain (2) · Sweden (2) · Ukraine (2) · Belgium (1) · Brazil (1)